Org 28611

Org 28611
Legal status
Legal status	CA: Schedule II; DE: NpSG (Industrial and scientific use only); UK: Under Psychoactive Substances Act;
Identifiers
	IUPAC name [1-(cyclohexylmethyl)-7-methoxyindol-3-yl]-[(3S)-3,4-dimethylpiperazin-1-yl]methanone;
CAS Number	639068-99-8 ;
PubChem CID	10091392;
ChemSpider	8266929 ;
UNII	1U7V49NTQG;
ChEMBL	ChEMBL1209709 ;
CompTox Dashboard (EPA)	DTXSID301029650 ;
Chemical and physical data
Formula	C23H33N3O2
Molar mass	383.536 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COc3cccc(c13)c(C(=O)N(CC2C)CCN2C)cn1CC4CCCCC4;
	InChI InChI=1S/C23H33N3O2/c1-17-14-25(13-12-24(17)2)23(27)20-16-26(15-18-8-5-4-6-9-18)22-19(20)10-7-11-21(22)28-3/h7,10-11,16-18H,4-6,8-9,12-15H2,1-3H3/t17-/m0/s1 ; Key:ONXJNAIZJKLJGA-KRWDZBQOSA-N ;
	(what is this?) (verify)

Org 28611 (SCH-900,111) is a drug developed by Organon International which acts as a potent cannabinoid receptor full agonist at both the CB₁ and CB₂ receptors. It was developed with the aim of finding a water-soluble cannabinoid agonist suitable for intravenous use as an analgesic,^[1] and while it achieved this aim and has progressed as far as Phase II clinical trials in humans as both a sedative and an analgesic, results against the comparison drugs (midazolam and morphine respectively) were not particularly favourable in initial testing.^[2]^[3]

Quick Facts Legal status, Identifiers ...

See also